Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 8
Submit an article Journal homepage
157
Views
0
CrossRef citations to date
0
Altmetric
Theme: Breast Cancer - Review

The challenges of individualized care for older patients with localized breast cancer

Ewa Mrózek Division of Medical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA. [email protected]; Division of Medical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA. [email protected]
,
Stephen P Povoski Division of Surgical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA; Division of Surgical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA
&
Charles L Shapiro Division of Medical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA; Division of Medical Oncology, The Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA
Pages 963-973 | Published online: 10 Jan 2014

References

  • Katz SJ, Morrow M. The challenge of individualizing treatments for patients with breast cancer. JAMA 307, 1379–1380 (2012).
  • Kelly CM, Pritchard KI. Personalized medicine: what exactly is it and can we truly measure it? J. Clin. Oncol. 30, 2173–2174 (2012).
  • DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics. CA Cancer J. Clin. 61, 409–418 (2011).
  • Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, Bethesda, MD, USA (2011).
  • Smith BD, Jiang J, McLaughlin SS et al. Improvement in breast cancer outcomes over time: are older women missing out? J. Clin. Oncol. 29, 4647–4653 (2011).
  • Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J. Clin. Oncol. 25, 1683–1690 (2007).
  • Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784–1792 (2005).
  • Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N. Engl. J. Med. 348, 1672–1680 (2003).
  • Humphrey LL, Helfand M, Chan BK et al. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 137(5 Part 1), 347–360 (2002).
  • Nelson HD, Tyne K, Naik A et al. Screening for breast cancer: an update for the U.S. Preventive Service Task Force. Ann. Intern. Med. 151, 727–737 (2009).
  • Nyström L, Andersson I, Bjurstam N et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359, 909–919 (2002).
  • Badgwell BD, Giordano SH, Duan ZZ et al. Mammography before diagnosis among women age 80 years and older with breast cancer. J. Clin. Oncol. 26, 2482–2488 (2008).
  • Smith RA, Saslow D, Sawyer KA et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J. Clin. 53, 141–169 (2003).
  • Nelson HD, Tyne K, Naik A et al. Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force. Agency for Healthcare Research and Quality (US), Rockville, MD, USA (2009).
  • No authors listed. Breast cancer screening in older women: American Geriatrics Society Clinical Practice Committee. J. Am. Geriatr. Soc. 48, 842–844 (2000).
  • Kagay CR, Quale C, Smith-Bindman R. Screening mammography in the American elderly. Am. J. Prev. Med. 31, 142–149 (2006).
  • Breen N, Wagener DK, Brown ML et al. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J. Natl Cancer Inst. 93, 1704–1713 (2001).
  • Walter LC, Covinsky KE. Cancer screening in elderly patients. JAMA 285, 2750–2756 (2001).
  • Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  • Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguishes tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
  • Jenkins EO, Deal AK, Anders CK et al. Breast cancer intrinsic subtypes by PAM50 in older women. J. Clin. Oncol. 30(Suppl.), Abstract 1524, (2012).
  • Durbecq V, Ameye L, Veys I et al. A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics. Crit. Rev. Oncol. Hematol. 67, 80–92 (2008).
  • Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst. 92, 550–556 (2000).
  • Dent R, Trudeau M, Pritchard KI et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
  • Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721–1728 (2007).
  • Königsberg R, Pfeiler G, Klement T et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (=65) patients. Eur. J. Cancer 48, 2962–2968 (2012).
  • Aapro M, Wildiers H. Triple-negative breast cancer in older population. Ann. Oncol. 23, 52–55 (2012).
  • Cheung K, Syed BM, Green AR et al. Clinical outcome of triple negative primary breast cancer in older women: comparison with their younger counterparts. J. Clin. Oncol. 29(Suppl.), Abstract 1057, (2011).
  • Cronin KA, Harlan LC, Dodd KW et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 9, 963–968 (2010).
  • de Munck L, Schaapveld M, Siesling S et al. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in The Netherlands. Breast Cancer Res. Treat. 129, 229–233 (2011).
  • Janssen-Heijnen ML, Maas HA, Houterman S et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur. J. Cancer 43, 2179–2193 (2007).
  • Fisher B, Bauer M, Margolese R et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N. Engl. J. Med. 312, 665–673 (1985).
  • Nattinger AB, Gottlieb MS, Hoffman RG et al. Minimal increase in use of breast-conserving surgery from 1986 to 1990. Med. Care 34, 479–489 (1996).
  • Gilligan MA, Kneusel RT, Hoffmann RG et al. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med. Care 40, 181–189 (2002).
  • Alderman AK, Bynum J, Sutherland J et al. Surgical treatment of breast cancer among the elderly in the United States. Cancer 117, 698–704 (2011).
  • Burak WE Jr, Agnese DM, Povoski SP. Advances in the surgical management of early stage invasive breast cancer. Curr. Probl. Surg. 41, 882–935 (2004).
  • Martelli G, Boracchi P, Ardoino I et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of randomized controlled trial. Ann. Surg. 256, 920–924 (2012).
  • Rudenstam CM, Zahrieh D, Forbes JF et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J. Clin. Oncol. 24, 337–344 (2006).
  • Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305, 569–575 (2011).
  • Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br. J. Cancer 96, 1025–1029 (2007).
  • Seo JH, Kim YH, Kim JS. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother. Pharmacol. 63, 261–266 (2009).
  • Syed BM, Al-Khyatt W, Johnston SJ et al. Long-term clinical outcome of oestrogen receptor positive operable primary breast cancer in older women: a large series from a single centre. Br. J. Cancer 104, 1393–1400 (2011).
  • Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. Br. J. Cancer 105, 1825–1829 (2011).
  • Hille U, Soergel P, Langer F et al. Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients. Breast J. 1, 145–150 (2012).
  • Wink CJ, Woensdregt K, Nieuwenhuijzen GA et al. Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. Ann. Surg. Oncol. 19, 1185–1191 (2012).
  • Wyld L, Garg DK, Kumar ID et al. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br. J. Cancer 90, 1486–1491 (2004).
  • Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 378, 1707–1716 (2011).
  • Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087–2106 (2005).
  • Veronesi U, Marubini E, Mariani L et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann. Oncol. 12, 997–1003 (2001).
  • Hughes K, Schnaper L, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med. 351, 971–977 (2004).
  • Hughes K, Schnaper L, Cirrincione C et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. Proc. Am. Soc. Clin. Oncol. 28(Suppl.), Abstarct 507 (2010).
  • Pötter R, Gnant M, Kwasny W et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 334–340 (2007).
  • Soulos PR, Yu JB, Roberts KB et al. Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J. Clin. Oncol. 30, 1601–1607 (2012).
  • Arthur DW, Vicini FA. Accelerated partial breast irradiation as a part of breast conservation therapy. J. Clin. Oncol. 23, 1726–1735 (2005).
  • Khan AJ, Vicini FA, Beitsch P et al. Local control, toxicity, and cosmesis in women >70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. Int. J. Radiat. Oncol. Biol. Phys. 84, 323–330 (2012).
  • Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care 6, 136–141 (2011).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies CF, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011).
  • Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431–2442 (2003).
  • Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486–492 (2007).
  • Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45–53 (2008).
  • Amir E, Seruga B, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systemic review and meta-analysis. J. Natl Cancer Inst. 103, 1299–1309 (2011).
  • Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J. Clin. Oncol. 30, 3665–3674 (2012).
  • Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 25, 829–836 (2007).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432–444 (2012).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
  • Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J. Clin. Oncol. 30, 2036–2038 (2012).
  • Kornblith AB, Kemeny M, Peterson BL et al. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95, 989–996 (2002).
  • Javid SH, Unger JM, Gralow JR et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist 17, 1180–1190 (2012).
  • Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293, 1073–1081 (2005).
  • Fargeot P, Bonneterre J, Roché H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J. Clin. Oncol. 22, 4622–4630 (2004).
  • Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N. Engl. J. Med. 360, 2055–2065 (2009).
  • Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 25, 3808–3815 (2007).
  • Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 24, 5381–5387 (2006).
  • Jones S, Holmes FA, O’Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J. Clin. Oncol. 27, 1177–1183 (2009).
  • Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  • Wittner BS, Sgroi DC, Ryan PD et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 15, 2988–2993 (2008).
  • Hassett MJ, Silver SM, Hughes ME et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J. Clin. Oncol. 30, 2218–2226 (2012).
  • Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
  • Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
  • Freedman RA, Hughes ME, Ottesen RA et al. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 15, 839–846 (2013).
  • Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811–7819 (2005).
  • Tarantini L, Gori S, Faggiano P et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann. Oncol. 23, 3058–3063 (2012).
  • Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285, 885–892 (2001).
  • Patnaik JL, Byers T, Diguiseppi C et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J. Natl Cancer Inst. 103, 1101–1111 (2011).
  • Mohile S, Fan L, Reeve E et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. J. Clin. Oncol. 29, 1458–1464 (2011).
  • Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13, 148–160 (2012).
  • Solomon D, Brown SA, Brummel-Smith K et al. Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. J. Am. Geriatr. Soc. 10, 1490–1494 (2003).
  • Sternberg SA, Wershof Schwartz A, Karunananthan S et al. The identification of frailty: a systematic literature review. J. Am. Geriatr. Soc. 11, 2129–2138 (2011).
  • Fried L, Tangen C, Walston J et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146–M156 (2001).
  • Walston J, Hadley EC, Ferrucci L et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J. Am. Geriatr. Soc. 54, 991–1001 (2006).
  • Ensrud KE, Ewing SK, Taylor BC et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch. Intern. Med. 168, 382–389 (2008).
  • Puts MT, Hardt J, Monette J et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J. Natl Cancer Inst. 104, 1133–1163 (2012).
  • Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 29, 3457–3465 (2011).
  • Kellen E, Bulens P, Deckx L et al. Identifying an accurate pre-screening tool in geriatric oncology. Crit. Rev. Oncol. Hematol. 75, 243–248 (2010).
  • Hamaker ME, Jonker JM, de Rooij SE et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 13, 437–444 (2012).
  • Dale W, Mohile SG, Eldadah BA et al. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J. Natl Cancer Inst. 104, 581–589 (2012).
  • Pierce BL, Ballard-Barbash R, Bernstein L et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 20, 3437–3444 (2009).
  • Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14, 414–420 (2003).
  • Bates T, Riley DL, Houghton J et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br. J. Surg. 78, 591–594 (1991).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.